Sanofi Consumer Healthcare India Ltd.
NSE: SANOFICONR · Pharmaceuticals
Snapshot
Unlock Sanofi Consumer Healthcare India Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sanofi Consumer Healthcare India Limited is a fast-moving consumer healthcare company that provides a range of products across allergy, physical wellness, and pain care segments. Its portfolio includes well-known brands such as Allegra, Combiflam, and Avil, distributed through a diverse network of pharmacies, hospitals, and e-commerce platforms.
Business Model
The company generates revenue by marketing and distributing over-the-counter and prescription-based consumer healthcare products to a wide network of distributors, wholesalers, and retail pharmacy chains. It operates as a subsidiary of Opella Healthcare Participations B.V., leveraging established global brands to capture market share in the Indian consumer health sector.
Growth Outlook
Growth is expected to be driven by the expansion of its consumer healthcare portfolio and the strengthening of its distribution network across both traditional retail and e-commerce channels. The company aims to leverage its strong brand equity in the allergy and pain management segments to penetrate deeper into the Indian market.
Key Risks
- Regulatory Risk. The company is subject to stringent government regulations regarding drug pricing and quality standards in the Indian pharmaceutical industry.
- Competitive Pressure. Intense competition from both domestic and multinational consumer healthcare companies may impact market share and pricing power.
- Supply Chain Dependency. Reliance on complex supply chains and third-party distributors poses risks to product availability and operational efficiency.
- Brand Reputation. Any adverse events or quality control issues related to its core product portfolio could significantly damage the company's brand equity.
Start your research today
Unlock AI insights, financials, peers and live data on Sanofi Consumer Healthcare India Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹979 Cr
TTM · standalone
NET PROFIT
₹280 Cr
TTM · standalone
EPS
₹121.44
TTM · standalone
RETURN ON EQUITY
92.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
113.0%
TTM · standalone
P/E
29.0×
Q2 FY27 · standalone
EV/EBITDA
19.5x
Q2 FY27 · standalone
EBITDA MARGIN
39.9%
TTM · standalone
NET PROFIT MARGIN
29.1%
Q2 FY27 · standalone
DEBT TO EQUITY
0.0x
Q2 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sanofi Consumer Healthcare India Ltd.SANOFICONR | ₹8,107 Cr | 29.0× | 19.51 | 22.7% | 39.9% | 92.5% | 113.0% | -27.3% |
Blue Jet Healthcare Ltd.BLUEJET | ₹9,353 Cr | 36.5× | 26.79 | -27.5% | 39.2% | 18.8% | 25.0% | -24.7% |
Aarti Pharmalabs LimitedAARTIPHARM | ₹8,060 Cr | 31.4× | 17.95 | 13.4% | 22.9% | 11.9% | 14.6% | +4.3% |
Symbiotec Pharmalab LimitedSYMBIOTEC | ₹7,871 Cr | — | — | — | 27.0% | — | — | — |
Sanofi India LimitedSANOFI | ₹7,715 Cr | 21.2× | 13.92 | -5.7% | 29.0% | 45.3% | 59.5% | -29.9% |
Supriya Lifescience LimitedSUPRIYA | ₹6,746 Cr | 34.0× | 22.27 | 28.1% | 34.5% | 18.1% | 23.8% | +7.9% |
As of Q2 FY27
Financials
Sanofi Consumer Healthcare India Ltd.
NSE: SANOFICONR · Pharmaceuticals
Snapshot
Unlock Sanofi Consumer Healthcare India Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sanofi Consumer Healthcare India Limited is a fast-moving consumer healthcare company that provides a range of products across allergy, physical wellness, and pain care segments. Its portfolio includes well-known brands such as Allegra, Combiflam, and Avil, distributed through a diverse network of pharmacies, hospitals, and e-commerce platforms.
Business Model
The company generates revenue by marketing and distributing over-the-counter and prescription-based consumer healthcare products to a wide network of distributors, wholesalers, and retail pharmacy chains. It operates as a subsidiary of Opella Healthcare Participations B.V., leveraging established global brands to capture market share in the Indian consumer health sector.
Growth Outlook
Growth is expected to be driven by the expansion of its consumer healthcare portfolio and the strengthening of its distribution network across both traditional retail and e-commerce channels. The company aims to leverage its strong brand equity in the allergy and pain management segments to penetrate deeper into the Indian market.
Key Risks
- Regulatory Risk. The company is subject to stringent government regulations regarding drug pricing and quality standards in the Indian pharmaceutical industry.
- Competitive Pressure. Intense competition from both domestic and multinational consumer healthcare companies may impact market share and pricing power.
- Supply Chain Dependency. Reliance on complex supply chains and third-party distributors poses risks to product availability and operational efficiency.
- Brand Reputation. Any adverse events or quality control issues related to its core product portfolio could significantly damage the company's brand equity.
Start your research today
Unlock AI insights, financials, peers and live data on Sanofi Consumer Healthcare India Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹979 Cr
TTM · standalone
NET PROFIT
₹280 Cr
TTM · standalone
EPS
₹121.44
TTM · standalone
RETURN ON EQUITY
92.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
113.0%
TTM · standalone
P/E
29.0x
Q2 FY27 · standalone
EV/EBITDA
19.5x
Q2 FY27 · standalone
EBITDA MARGIN
39.9%
TTM · standalone
NET PROFIT MARGIN
29.1%
Q2 FY27 · standalone
DEBT TO EQUITY
0.0x
Q2 FY27 · standalone
Peers · Pharmaceuticals
As of Q2 FY27